Bristol-Myers Squibb Company Stock Price, News & Analysis (NYSE:BMY)

$61.32 -0.55 (-0.89 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$61.87
Today's Range$60.99 - $61.89
52-Week Range$46.01 - $66.10
Volume3.94 million shs
Average Volume8.63 million shs
Market Capitalization$100.36 billion
P/E Ratio20.63
Dividend Yield2.55%
Beta1.18

About Bristol-Myers Squibb Company (NYSE:BMY)

Bristol-Myers Squibb Company logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:BMY
  • CUSIP: 11012210
  • Web: www.bms.com
Debt:
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.46%
Price-To-Earnings:
  • Trailing P/E Ratio: 20.63
  • Forward P/E Ratio: 20.51
  • P/E Growth: 2.41
Sales & Book Value:
  • Annual Sales: $19.427 billion
  • Price / Sales: 5.17
  • Cash Flow: $3.08 per share
  • Price / Cash: 19.89
  • Book Value: $9.11 per share
  • Price / Book: 6.73
Dividend:
  • Annual Dividend: $1.56
  • Dividend Yield: 2.6%
Profitability:
  • Trailing EPS: $2.54
  • Net Income: $4.457 billion
  • Net Margins: 20.56%
  • Return on Equity: 32.41%
  • Return on Assets: 14.66%
Misc:
  • Employees: 25,000
  • Outstanding Shares: 1,636,700,000
 
Frequently Asked Questions for Bristol-Myers Squibb Company (NYSE:BMY)

What is Bristol-Myers Squibb Company's stock symbol?

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company declared a quarterly dividend on Wednesday, September 13th. Stockholders of record on Friday, October 6th will be paid a dividend of $0.39 per share on Wednesday, November 1st. This represents a $1.56 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Thursday, October 5th. View Bristol-Myers Squibb Company's Dividend History.

How were Bristol-Myers Squibb Company's earnings last quarter?

Bristol-Myers Squibb Company (NYSE:BMY) announced its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.02. The biopharmaceutical company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb Company had a return on equity of 32.41% and a net margin of 20.56%. The company's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 EPS. View Bristol-Myers Squibb Company's Earnings History.

When will Bristol-Myers Squibb Company make its next earnings announcement?

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Bristol-Myers Squibb Company.

What guidance has Bristol-Myers Squibb Company issued on next quarter's earnings?

Bristol-Myers Squibb Company issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus estimate of $2.96.

Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?

18 brokerages have issued twelve-month target prices for Bristol-Myers Squibb Company's stock. Their predictions range from $49.00 to $75.00. On average, they anticipate Bristol-Myers Squibb Company's stock price to reach $63.92 in the next year. View Analyst Ratings for Bristol-Myers Squibb Company.

What are Wall Street analysts saying about Bristol-Myers Squibb Company stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

  • 1. According to Zacks Investment Research, "Bristol-Myers reported mixed results for the third-quarter wherein earnings missed expectations although revenue beat on the same. The miss in earnings was attributable to lower gross margin which in turn was due to product mix and decline in virology business. The increase in earnings guidance was encouraging. The company’s blockbuster immuno-oncology Opdivo continues to perform well along with, Eliquis and Orencia. The company is looking to expand Opdivo’s label further and recently won FDA approvals for liver and colorectal cancers which should boost performance. The company is also looking to counter generic threat for its key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie and Halozyme. However, Opdivo is currently facing competitive challenges in the United States. The virology business is also under pressure. Shares of the company have underperformed the industry in the year so far." (11/2/2017)
  • 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 3. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • 4. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Who are some of Bristol-Myers Squibb Company's key competitors?

Who are Bristol-Myers Squibb Company's key executives?

Bristol-Myers Squibb Company's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer (Age 52)
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations (Age 57)
  • Louis S. Schmukler, President - Global Manufacturing and Supply (Age 61)
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President (Age 51)
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer (Age 56)
  • Sandra Leung, Executive Vice President, General Counsel (Age 56)
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer (Age 50)
  • Paul von Autenried, Senior Vice President, Chief Information Officer (Age 55)
  • Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer (Age 56)
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller (Age 61)

Who owns Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.64%), Bank of New York Mellon Corp (1.15%), Ameriprise Financial Inc. (0.89%), Legal & General Group Plc (0.53%), Swiss National Bank (372,180.00%) and Schwab Charles Investment Management Inc. (0.34%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.

Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Neuberger Berman Group LLC, Janus Henderson Group PLC, Ameriprise Financial Inc., Assetmark Inc., Sector Gamma AS, State of Tennessee Treasury Department and California State Teachers Retirement System. Company insiders that have sold Bristol-Myers Squibb Company company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Parnassus Investments CA, Bank of New York Mellon Corp, Amundi Pioneer Asset Management Inc., Canada Pension Plan Investment Board, Prudential Financial Inc., Vaughan David Investments Inc. IL and Sabal Trust CO. View Insider Buying and Selling for Bristol-Myers Squibb Company.

How do I buy Bristol-Myers Squibb Company stock?

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb Company's stock price today?

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $61.32.

How big of a company is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company has a market capitalization of $100.36 billion and generates $19.427 billion in revenue each year. The biopharmaceutical company earns $4.457 billion in net income (profit) each year or $2.54 on an earnings per share basis. Bristol-Myers Squibb Company employs 25,000 workers across the globe.

How can I contact Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company's mailing address is 345 PARK AVE, NEW YORK, NY 10154, United States. The biopharmaceutical company can be reached via phone at +1-212-5464000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb Company (NYSE BMY)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  669 (Vote Outperform)
Underperform Votes:  635 (Vote Underperform)
Total Votes:  1,304
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $63.92 (4.25% upside)
Consensus Price Target History for Bristol-Myers Squibb Company (NYSE:BMY)
Price Target History for Bristol-Myers Squibb Company (NYSE:BMY)
Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/30/2017SunTrust Banks, Inc.UpgradeHold -> BuyN/AView Rating Details
10/27/2017Credit Suisse GroupReiterated RatingHold$58.00 -> $61.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$60.00N/AView Rating Details
10/26/2017BMO Capital MarketsSet Price TargetSell$49.00N/AView Rating Details
10/25/2017Citigroup Inc.Set Price TargetBuy$72.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetOutperform$61.00 -> $72.00N/AView Rating Details
10/16/2017Jefferies Group LLCDowngradeBuy -> Hold$72.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetEqual Weight$58.00 -> $65.00N/AView Rating Details
9/19/2017Cowen and CompanyReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/7/2017The Goldman Sachs Group, Inc.Reiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetHold$54.00 -> $55.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/21/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00N/AView Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$0.66N/AView Earnings Details
10/26/2017Q3 2017$0.77$0.75$5.20 billion$5.25 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
2017 EPS Consensus Estimate: $2.87
2018 EPS Consensus Estimate: $3.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.70$0.72$0.71
Q2 20173$0.70$0.76$0.73
Q3 20174$0.75$0.78$0.77
Q4 20173$0.64$0.68$0.66
Q1 20181$0.74$0.74$0.74
Q2 20181$0.75$0.75$0.75
Q3 20181$0.78$0.78$0.78
Q4 20181$0.81$0.81$0.81
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
Most Recent Dividend:11/1/2017
Annual Dividend:$1.56
Dividend Yield:2.54%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:61.42% (Trailing 12 Months of Earnings)
52.17% (Based on This Year's Estimates)
49.21% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Dividend History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/13/2017quarterly$0.392.49%10/5/201710/6/201711/1/2017
6/13/2017quarterly$0.392.86%7/5/20177/7/20178/1/2017
3/2/2017quarterly$0.392.72%4/5/20174/7/20175/1/2017
12/8/2016quarterly$0.392.73%1/4/20171/6/20172/1/2017
8/3/2016quarterly$0.382.02%10/5/201610/7/201611/1/2016
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013
12/4/2012quarterly$0.351/4/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Company (NYSE BMY)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.51%
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.00View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.00View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.00View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.84View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.00View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bristol-Myers Squibb Company (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Company (NYSE BMY)
Source:
DateHeadline
Novartis on the Street: Analysts’ Recommendations in NovemberNovartis on the Street: Analysts’ Recommendations in November
finance.yahoo.com - November 17 at 4:13 PM
Industry Group Rank Limit Bristol-Myers Squibb Co (BMY) RatingIndustry Group Rank Limit Bristol-Myers Squibb Co (BMY) Rating
investorplace.com - November 17 at 2:42 PM
Guardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with Bristol-Myers SquibbGuardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with Bristol-Myers Squibb
www.bizjournals.com - November 16 at 10:03 PM
Bristol-Myers Squibb (BMY) Presents at Jefferies 2017 London Healthcare Conference (Transcript)Bristol-Myers Squibb (BMY) Presents at Jefferies 2017 London Healthcare Conference (Transcript)
seekingalpha.com - November 16 at 12:04 PM
Ultragenyx Seeks An FDA Win For Biologic Therapy CandidateUltragenyx Seeks An FDA Win For Biologic Therapy Candidate
finance.yahoo.com - November 16 at 12:04 PM
FY2021 EPS Estimates for Bristol-Myers Squibb Company Reduced by Analyst (BMY)FY2021 EPS Estimates for Bristol-Myers Squibb Company Reduced by Analyst (BMY)
www.americanbankingnews.com - November 15 at 4:58 PM
Contrasting AMAG Pharmaceuticals (AMAG) and Bristol-Myers Squibb (BMY)Contrasting AMAG Pharmaceuticals (AMAG) and Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - November 14 at 9:26 PM
Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb - BarronsWhich Will Pfizer Buy? Biogen or Bristol-Myers Squibb - Barron's
www.barrons.com - November 14 at 5:47 AM
BRIEF-Syngene International ‍expands collaboration with Bristol-Myers SquibbBRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb
www.reuters.com - November 14 at 12:46 AM
Bristol-Myers Squibb Brings Out Its Ace Card In The Midst Of An IDO Inhibitor BattleBristol-Myers Squibb Brings Out Its Ace Card In The Midst Of An IDO Inhibitor Battle
seekingalpha.com - November 14 at 12:46 AM
ETFs with exposure to Bristol-Myers Squibb Co. : November 13, 2017ETFs with exposure to Bristol-Myers Squibb Co. : November 13, 2017
finance.yahoo.com - November 14 at 12:46 AM
[$$] Arcus Biosciences Rounds Up $107 Million for Cancer Combination Therapy[$$] Arcus Biosciences Rounds Up $107 Million for Cancer Combination Therapy
finance.yahoo.com - November 14 at 12:46 AM
$5.29 Billion in Sales Expected for Bristol-Myers Squibb Company (BMY) This Quarter$5.29 Billion in Sales Expected for Bristol-Myers Squibb Company (BMY) This Quarter
www.americanbankingnews.com - November 13 at 10:50 PM
Bristol-Myers Squibb (BMY) Says Encouraging Response Observed with Opdivo Plus ...Bristol-Myers Squibb (BMY) Says Encouraging Response Observed with Opdivo Plus ...
www.streetinsider.com - November 11 at 9:33 PM
First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017
finance.yahoo.com - November 11 at 9:33 PM
Bristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in Chronic PhaseBristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in Chronic Phase
www.streetinsider.com - November 11 at 4:31 PM
Rating for Bristol-Myers Squibb Co (BMY) Drops….. Wilting Earnings Visibility - Investorplace.comRating for Bristol-Myers Squibb Co (BMY) Drops….. Wilting Earnings Visibility - Investorplace.com
investorplace.com - November 11 at 8:19 AM
Bristol-Myers Squibb Company (BMY) Expected to Post Earnings of $0.67 Per ShareBristol-Myers Squibb Company (BMY) Expected to Post Earnings of $0.67 Per Share
www.americanbankingnews.com - November 11 at 1:28 AM
BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial FibrillationBMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation
finance.yahoo.com - November 10 at 8:20 PM
Bristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in ... - StreetInsider.comBristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in ... - StreetInsider.com
www.streetinsider.com - November 10 at 3:17 PM
Bristol-Myers Squibb (BMY) Says Encouraging Response Observed with Opdivo Plus Investigational IDO1 Inhibitor ... - StreetInsider.comBristol-Myers Squibb (BMY) Says Encouraging Response Observed with Opdivo Plus Investigational IDO1 Inhibitor ... - StreetInsider.com
www.streetinsider.com - November 10 at 3:17 PM
U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseU.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
finance.yahoo.com - November 10 at 12:43 PM
Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003
finance.yahoo.com - November 10 at 12:43 PM
Are Bristol-Myers Squibb Company’s (BMY) Interest Costs Too High?Are Bristol-Myers Squibb Company’s (BMY) Interest Costs Too High?
finance.yahoo.com - November 10 at 12:43 PM
Rating for Bristol-Myers Squibb Co (BMY) Drops….. Wilting Earnings VisibilityRating for Bristol-Myers Squibb Co (BMY) Drops….. Wilting Earnings Visibility
investorplace.com - November 10 at 11:26 AM
BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumorsBRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
www.reuters.com - November 9 at 5:50 PM
Bristol-Myers Squibb (BMY) to Highlight Clinical and Translational Research at SITCBristol-Myers Squibb (BMY) to Highlight Clinical and Translational Research at SITC
www.streetinsider.com - November 9 at 5:50 PM
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid TumorsBristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
finance.yahoo.com - November 9 at 5:50 PM
Bristol-Myers Squibb (BMY) & Five Prime (FPRX) Announce Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 ... - StreetInsider.comBristol-Myers Squibb (BMY) & Five Prime (FPRX) Announce Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 ... - StreetInsider.com
www.streetinsider.com - November 9 at 5:50 PM
BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers SquibbBRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
www.businessinsider.com - November 8 at 9:08 PM
Bristol-Myers Squibb (BMY) to Highlight Clinical and Translational Research at SITC - StreetInsider.comBristol-Myers Squibb (BMY) to Highlight Clinical and Translational Research at SITC - StreetInsider.com
www.streetinsider.com - November 8 at 4:06 PM
Bristol-Myers Squibb to Take Part in Jefferies London Healthcare ConferenceBristol-Myers Squibb to Take Part in Jefferies London Healthcare Conference
finance.yahoo.com - November 8 at 4:06 PM
Infinity (INFI) Q3 Loss Narrower than Expected, View IntactInfinity (INFI) Q3 Loss Narrower than Expected, View Intact
finance.yahoo.com - November 8 at 4:06 PM
BRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levelsBRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels
www.reuters.com - November 7 at 7:33 PM
Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingBristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - November 7 at 7:32 PM
Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaOpdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
finance.yahoo.com - November 7 at 7:32 PM
Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)
finance.yahoo.com - November 6 at 5:46 PM
Bristol-Myers Squibb’s Valuations after Its 3Q17 EarningsBristol-Myers Squibb’s Valuations after Its 3Q17 Earnings
finance.yahoo.com - November 6 at 5:46 PM
Outcome Health losing major advertisers following allegations of misleading clientsOutcome Health losing major advertisers following allegations of misleading clients
finance.yahoo.com - November 6 at 5:46 PM
PHOTO ADVISORY: Eric Stonestreet Visits Lung Cancer Alliance’s Lung Love Walk Houston to Raise Awareness of Cancer ResearchPHOTO ADVISORY: Eric Stonestreet Visits Lung Cancer Alliance’s Lung Love Walk Houston to Raise Awareness of Cancer Research
finance.yahoo.com - November 5 at 4:31 PM
Investors Buy High Volume of Put Options on Bristol-Myers Squibb (BMY)Investors Buy High Volume of Put Options on Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - November 4 at 1:28 AM
Bristol-Myers Squibb Co (BMY) Sees Downgrade….. Poor Earnings MomentumBristol-Myers Squibb Co (BMY) Sees Downgrade….. Poor Earnings Momentum
investorplace.com - November 3 at 10:18 PM
Eliquis: A Look at BMY’s Blockbuster Cardiovascular Drug in 3Q17Eliquis: A Look at BMY’s Blockbuster Cardiovascular Drug in 3Q17
finance.yahoo.com - November 3 at 10:18 PM
Bristol-Myers Squibb’s 3Q17 Earnings: Immunoscience ProductsBristol-Myers Squibb’s 3Q17 Earnings: Immunoscience Products
finance.yahoo.com - November 3 at 5:15 PM
Bristol-Myers Squibb Co (BMY) Sees Downgrade….. Poor Earnings MomentumBristol-Myers Squibb Co (BMY) Sees Downgrade….. Poor Earnings Momentum
investorplace.com - November 3 at 10:41 AM
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-WrightZacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
finance.yahoo.com - November 3 at 8:32 AM
Bristol-Myers Squibb’s 3Q17 Earnings: Virology ProductsBristol-Myers Squibb’s 3Q17 Earnings: Virology Products
finance.yahoo.com - November 3 at 8:32 AM
Bristol-Myers Squibb (BMY) to Showcase Progress in Researching Personalized ...Bristol-Myers Squibb (BMY) to Showcase Progress in Researching Personalized ...
www.streetinsider.com - November 2 at 10:17 PM
Bristol-Myers Squibb to Showcase Company’s Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of ...Bristol-Myers Squibb to Showcase Company’s Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of ...
www.businesswire.com - November 2 at 10:17 PM
Bristol-Myers Squibb to Showcase Company’s Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual MeetingBristol-Myers Squibb to Showcase Company’s Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
finance.yahoo.com - November 2 at 10:17 PM

Social Media

Financials

Chart

Bristol-Myers Squibb Company (NYSE BMY) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.